Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Other solid neoplasm 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Sarcoma, Synovial 1Sarcoma 1Rhabdoid Tumor 1Mesothelioma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Hematologic Neoplasms 1

Interventions

tislelizumab 2tazemetostat 2belinostat 2spartalizumab 1pembrolizumab 1fludarabine phosphate 1fludarabine 1Temozolomide 1Sorafenib 1Rifampin 1Quality of Life 1Plicamycin 1Pemetrexed 1Patient Reported Outcome Measures 1PM 01183 1OSI 930 1Nivolumab 1Molecular Diagnostic Techniques 1LY2940680 1Itraconazole 1Irinotecan 1Immunotherapy, Adoptive 1Immunotherapy 1Imatinib Mesylate 1Fluorouracil 1Fluorodeoxyglucose F18 1Erlotinib Hydrochloride 1Drug Therapy 1Doxepin 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mesothelioma × Rifampin × Sarcoma × Clear all
NCT04537715 2025-02-19

Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels

Ipsen

Phase 1 Completed
42 enrolled 39 charts
LymphoidOther hematologic neoplasmOther solid neoplasmSarcomaThoracic

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Mesothelioma, Sarcoma, Sarcoma, Synovial, Lymphoma, Large B-Cell, Diffuse, Rhabdoid Tumor, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡